Feb 7 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Feb 7. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Feb 7 Today - Breaking & Trending Today

Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment

MELBOURNE, Australia, Feb. 7, 2023 /PRNewswire/ Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug application (IND) for its innovative drug HP518, an oral chimeric degrader targeting androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). HP518 is currently in Phase I clinical trials in Australia. The open-label study approved by FDA will assess the safety, pharmacokinetics, and anti-tumor activity of HP518. "HP518 is a novel drug expected to address the unmet clinical needs of prostate cancer treatment," said Yuanwei Chen, Ph.D., President and CEO of Hinova. "The available study results of HP518 strengthen our confidence that HP518 is a potentially new treatment for drug resistant prostate cancer. We are ....

Yuanwei Chen , Prnewswire Hinova Pharmaceuticals Inc , Drug Administration , Pharmaceuticals Inc , Feb 7 , 023 Prnewswire Hinova Pharmaceuticals Inc , A Clinical Stage Biopharmaceutical Company Focusing On Developing Novel Therapeutics For Cancers And Metabolic Diseases , Ecently Announced That The Us Food And Drug Administration Fda Has Cleared Company 39s Investigational New Application Ind For Its Innovative Hp518 , N Oral Chimeric Degrader Targeting Androgen Receptor Ar For The Treatment Of Metastatic Castration Resistant Prostate Cancer Mcrpc Hp518 Is Currently In Phasei Clinical Trials Australia Open Label Study Approved By Fda Will Assess Safety , Nd Anti Tumor Activity Of Hp518 Quot Isa Novel Drug Expected To Address The Unmet Clinical Needs Prostate Cancer Treatment , Uot Said Yuanwei Chen , Resident And Ceo Of Hinova Quot The Available Study Results Hp518 Strengthen Our Confidence That Isa Potentially New Treatment For Drug Resistant Prostate Cancer We Are Making Full Efforts To Advance Clinical , Oping Hp518 Will Provide More Clinical Benefits To Patients Worldwide In The Future Quot Has Been Discovered And Developed Through Hinova 39s Targeted Protein Degradation Drug Discovery Platform It Potential Overcome Resistance Of Prostate Cancer That Is Due Some Specific Ar Mutations Isa Validated Therapeutic Target Treat During Treatment , Rug Resistance Becomes Inevitable Due To Multiple Mechanisms , Ncluding Ar Amplification Or Mutations , Tc In Preclinical Studies , P518 Showed Excellent Selectivity And Degradation Activity Against Wild Type Ar Some Specific Mutants That Are Resistant To Enzalutamide Hp518 Also Demonstrated Antitumor Efficacy In Xenograft Mouse Models About Hinova Is An International Clinical Stage Biopharmaceutical Company Engaged The Development Of Innovative Deuterated Chimeric Degraders For Cancers Metabolic Diseases Has Establisheda Targeted Protein Drug Discovery Platform , Hich Allows Hinova To Screen For Protein Degradation Activity Rapidly And Accomplish Efficient Design Optimization Of Chimeric Degraders Furthermore , Inova Has Profound Experience In Chemical Manufacturing Control Cmc Of Chimeric Degrader Compounds For More Information , Lease Visit Http Www Hinovapharma Com En ,

Velocity 678 Comes Out of Stealth

SINGAPORE, Feb. 7, 2023 /PRNewswire/ Velocity 678 (V678), a joint partnership between Momentum Commerce, SnT Global Logistics, and Aiken Group, is proud to announce its appointment of Kenneth Chiew as General Manager. Based in Singapore & Malaysia, V678 is a leading enabler in Southeast Asia, offering end-to-end live commerce solutions such as live streaming, short video content production, social media operation, strategy planning, TikTok shop management, campaign optimization, ecommerce operations, and influencer marketing. As Aiken Group's Social Commerce arm, V678 is also a notable TikTok Shop Partner (TSP) and Multi-Channel Network (MCN) in the region, aiming to drive brand awareness and added value for social commerce. Kenneth Chiew, General Manager of Velocity 678 As General Manager, Kenneth will report to Joseph Chua, CEO of Aiken Group and will lead V678 to drive transformational growth and commercial revenue for brands. He will spearhead strategic relationships with ....

Republic Of , Kuala Lumpur , United Kingdom , Joseph Chua , Eddy Yap , Kenneth Chiew , Aiken Group Social Commerce , Consumer Electronics , Channel Network , Haiken Group , Momentum Commerce , Snt Global Logistics , Southeast Asia , Social Commerce , Tiktok Shop Partner , Multi Channel Network , General Manager , Business Director , Farm Fresh , Live Commerce Industry , Lazada Malaysia , Peter Ressel , Best In Class Omnichannel Fulfilment Partner , New Retail , Skin Care , Feb 7 ,